Phase III Randomized Study of SB 5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Phase III Randomized Study of SB 5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

Published:2017-11-21 Issue:1 Volume:70 Page:40-48
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Weinblatt Michael E.¹,Baranauskaite Asta²,Niebrzydowski Jaroslaw³,Dokoupilova Eva⁴,Zielinska Agnieszka⁵,Jaworski Janusz⁶,Racewicz Artur⁷,Pileckyte Margarita²,Jedrychowicz‐Rosiak Krystyna⁸,Cheong Soo Yeon⁹,Ghil Jeehoon⁹,Sokolovic S.,Mekic M.,Prodanovic N.,Gajic B.,Karaselimovic‐Dzambasovic E.,Pojskic B.,Toncheva A.,Dimitar P.,Rodina L.,Geneva‐Popova M.,Staykov I.,Stoilov R.,Podrazilova L.,Mosterova Z.,Simkova G.,Kopackova J.,Stejfova Z.,Vencovsky J.,Urbanova Z.,Janska L.,Galatíkova D.,Stropuviene S.,Sniuoliene I.,Sitek‐Ziolkowska K.,Rell‐Bakalarska M.,Kolasa R.,Daniluk S.,Sliwowska B.,Bartosik‐Twardowska M.,Brzezicki J.,Konieczny M.,Jeka S.,Choe J.,Bae S.,Kang Y.,Prystupa L.,Vyacheslav Z.,Gasanov I.,Yatsyshyn R.,Rekalov D.,Iaremenko O.,Stanislavchuk M.,Tseluyko V.

Affiliation:

1. Brigham and Women's Hospital Boston Massachusetts

2. Lithuanian University of Health Sciences Kaunas Lithuania

3. Medica Pro Familia Gdynia Poland

4. Medical Plus Uherske Hradiste Czech Republic

5. Medica Pro Familia Warsaw Poland

6. Reumatika Centrum Reumatologii Warsaw Poland

7. Zdrowie Osteo‐Medic Białystok Poland

8. Mazowieckie Centrum Badań Klinicznych Grodzisk Mazowiecki Poland

9. Samsung Bioepis Incheon Republic of Korea

Funder

Samsung